New testing strategies for prostate cancer, including noninvasive saliva tests, may be close to hand, now that an in-depth study of DNA samples from more than 140,000 men has implicated 63 additional genetic variants in prostate cancer risk. By adding the newfound variants to previously known prostate cancer risk variants, scientists based at the Institute of Cancer Research (ICR), London, have devised a new test that can identify men who are most likely to develop prostate cancer. The new test could redraw risk strata: The test’s highest level of risk, the top 1%, consists of men who are nearly six times more likely to develop prostate cancer than the population average—taking the absolute risk from around 1 in 11 to 1 in 2. At the top 10% are men who are 2.7 times more likely to develop the disease—corresponding to a risk of almost one in four. ...